Table 1.
Baseline Characteristics According to rSS
| rSS = 0 (n = 1,084) |
rSS >0–2 (n = 523) |
rSS >2–8 (n = 578) |
rSS >8 (n = 501) |
p Value All Groups |
|
|---|---|---|---|---|---|
| Age, yrs | 59 (51–68) | 59 (51–69) | 61 (53–69) | 63 (55–72) | <0.001 |
| Male | 66.6% (722/1,084) | 64.6% (338/523) | 70.4% (407/578) | 68.7% (344/501) | 0.17 |
| Weight, kg | 88.0 (75.0–101.9) | 85.0 (75.0–98.0) | 88.0 (77.0–101.0) | 85.0 (75.0–98.0) | 0.13 |
| Diabetes | 25.0% (270/1,079) | 28.9% (151/522) | 31.3% (179/572) | 34.1% (170/499) | <0.01 0.02 |
| Insulin-treated | 6.4% (69/1,079) | 9.4% (49/522) | 7.9% (45/572) | 10.6% (53/499) | <0.01 0.02 |
| Hypertension | 62.0% (669/1079) | 64.0% (333/520) | 70.9% (409/577) | 70.3% (352/501) | <0.001 |
| Hyperlipidemia | 54.0% (576/1,067) | 56.1% (289/515) | 57.9% (329/568) | 60.4% (300/497) | 0.09 |
| Current smoker | 35.8% (387/1,081) | 37.9% (198/522) | 35.0% (201/575) | 31.1% (155/499) | 0.13 |
| Previous MI | 25.7% (273/1,063) | 28.7% (147/513) | 32.1% (181/564) | 34.3% (169/492) | <0.01 |
| Previous PTCA | 44.0% (477/1,083) | 45.5% (237/521) | 46.0% (266/578) | 41.1% (205/499) | 0.37 |
| Renal insufficiency* | 14.0% (143/1,019) | 14.9% (73/491) | 16.1% (87/540) | 18.8% (86/457) | 0.12 |
| Baseline cardiac biomarker elevation | 57.5% (583/1,014) | 57.7% (280/485) | 58.9% (313/531) | 68.5% (315/460) | <0.001 |
| Baseline troponin elevation | 59.8% (553/925) | 57.5% (263/457) | 58.1% (289/497) | 67.5% (295/437) | <0.01 |
| ST-segment deviation >1 mm | 25.3% (274/1,084) | 22.9% (120/523) | 26.1% (151/578) | 27.3% (137/501) | 0.41 |
| Baseline cardiac biomarker elevation or ST-segment deviation | 67.0% (692/1,033) | 66.6% (329/494) | 68.1% (368/540) | 75.9% (356/469) | <0.01 |
| TIMI risk score | |||||
| Low (0–2) | 18.1% (157/866) | 17.8% (77/432) | 14.5% (70/484) | 11.6% (47/404) | 0.01 |
| Intermediate (3–4) | 61.0% (528/866) | 61.3% (265/432) | 56.4% (273/484) | 55.4% (224/404) | 0.12 |
| High (5–7) | 20.9% (181/866) | 20.8% (90/432) | 29.1% (141/484) | 32.9% (133/404) | <0.001 |
| Ejection fraction, % | 66.70 (59.00–73.50) | 67.50 (59.30–73.80) | 66.40 (58.90–72.50) | 62.30 (53.10–71.80) | <0.001 |
| Ejection fraction <35% | 0.6% (4/718) | 0.9% (3/335) | 1.1% (4/356) | 4.0% (13/325) | <0.001 |
| Number with 2-vessel CAD | 40.6% (440/1,084) | 41.9% (219/523) | 36.6% (209/571) | 27.4% (135/493) | <0.001 |
| Number with 3-vessel CAD | 25.2% (273/1,084) | 35.8% (187/523) | 51.5% (294/571) | 64.5% (318/493) | <0.001 |
| Lesions per patient | 3.01 ± 1.79 (1,083) | 3.46 ± 1.83 (523) | 4.22 ± 2.06 (568) | 5.08 ± 2.43 (493) | <0.001 |
| PCI vessel | |||||
| LAD | 41.7% (602/1,444) | 39.2% (291/743) | 36.9% (267/724) | 21.0% (111/529) | <0.001 |
| RCA | 31.7% (458/1,444) | 32.8% (244/743) | 36.2% (262/724) | 40.3% (213/529) | <0.001 |
| LCX | 26.6% (384/1,444) | 28.0% (208/743) | 26.9% (195/724) | 38.8% (205/529) | <0.001 |
| Lesion severity | |||||
| MACC B1 | 31.5% (455/1,444) | 28.3% (210/743) | 30.0% (217/724) | 27.2% (144/529) | 0.20 |
| MACC B2 | 22.0% (318/1,444) | 20.9% (155/743) | 21.8% (158/724) | 18.1% (96/529) | 0.28 |
| MACC C | 34.7% (501/1,444) | 36.2% (269/743) | 38.7% (280/724) | 46.7% (247/529) | <0.001 |
| Lesion length >20 mm | 18.3% (259/1,417) | 19.2% (140/731) | 22.3% (156/701) | 26.8% (134/500) | <0.001 |
| Moderate/severe tortuosity | 2.3% (33/1,442) | 1.9% (14/741) | 3.5% (25/719) | 1.9% (10/528) | 0.16 |
| Severe calcification | 3.1% (44/1,413) | 1.4% (10/726) | 2.9% (20/700) | 5.2% (27/523) | <0.01 |
| Thrombus | 1.4% (20/1,444) | 1.7% (13/751) | 5.1% (40/778) | 9.9% (62/624) | <0.001 |
| Ulceration | 3.4% (49/1,439) | 5.1% (38/740) | 4.9% (35/720) | 5.9% (31/526) | 0.06 |
| Aneurysm | 1.3% (18/1,440) | 0.3% (2/741) | 1.5% (11/720) | 1.0% (5/526) | 0.08 |
| Ectasia | 5.0% (72/1,440) | 4.5% (33/741) | 4.7% (34/720) | 8.4% (44/525) | <0.01 |
| Drug-eluting stent | 86.9% (942/1,084) | 84.6% (439/519) | 86.8% (485/559) | 78.5% (376/479) | <0.001 |
| Bare-metal stent | 12.0% (130/1,084) | 15.0% (78/519) | 15.7% (88/559) | 15.7% (75/479) | 0.08 |
| Baseline SYNTAX score | 7.5 ± 5.6 | 9.3 ± 6.1 | 12.6 ± 6.9 | 21.7 ± 8.6 | <0.001 |
| Residual SYNTAX score | 0 | 1.5 ± 0.5 | 5.2 ± 1.6 | 15.8 ± 6.5 | <0.001 |
| Delta† SYNTAX score | 7.3 ± 5.4 | 7.5 ± 6.1 | 6.9 ± 6.3 | 5.7 ± 6.4 | 0.15 |
Values are median (IQR), % (n/N), or mean ± SD (N).
*
Renal insufficiency is defined as a calculated creatinine clearance rate <60 ml/min determined by the Cockcroft-Gault equation.
†
Delta SYNTAX score represents the burden of disease removed by PCI.
CAD = coronary artery disease; IQR = interquartile range; LAD = left anterior descending artery; LCX = left circumflex artery; MACC = Modified American College of Cardiology/American Heart Association stenosis morphology classification; MI = myocardial infarction; PTCA = percutaneous transluminal coronary angioplasty; RCA = right coronary artery; rSS = residual Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery score; SYNTAX= Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; TIMI = Thrombolysis In Myocardial Infarction.